• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novartis Ag ADR (NY: NVS )

    106.43 -0.65 (-0.61%)
    Streaming Delayed Price Updated: 10:13 AM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Novartis Ag ADR

    < Previous 1 2
    ...
    17 18 19 20 21 22 23 24 25
    ...
    42 43 Next >
    Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
    Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology. 
    Via Benzinga
    3 Biotech Companies to Watch in 2023
    These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year. 
    Via InvestorPlace
    CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
    Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
    Via Investor's Business Daily
    2 Top Biotech Stocks to Buy Right Now
    These two pharmaceutical companies pay market-beating dividends to shareholders. 
    Via The Motley Fool
    GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
    GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.' 
    Via Benzinga
    Hopeful Golden Cross Forms On Novartis's Chart
    Via Benzinga
    5 Value Stocks In The Healthcare Sector
    Via Benzinga
    A Bullish Sign Appears On Novartis's Chart
    Via Benzinga
    2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
    These two biotechs are flying high right now. 
    Via The Motley Fool
    Elon Musk Tells Employees Tesla Will Be 'Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter 'Should Feel Faster': Today's Top Stories
    Reuters 
    Via Benzinga
    Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug
    Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower... 
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
    Via Benzinga
    Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial
    Via Benzinga
    3 Ridiculously Cheap Dividend Stocks That Yield More Than 3%
    You're getting a lot of bang for your buck with these stocks. 
    Via The Motley Fool
    Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
    Via Benzinga
    Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
    Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
    Via MarketBeat
    Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?
    The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI... 
    Via Benzinga
    A Career Politician Who Regularly Trades The SPY, Picked Up There 3 High Yielding ETFs Instead
    Representative Robert Wittman (R-VA) is the vice-ranking member of the House Armed Services Committee and also serves on the Committee on Natural Resources. 
    Via Benzinga
    Novartis Shares Detailed Results From Experimental Drug For Rare Blood Disorder
    Via Benzinga
    Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
    Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data. 
    Via Investor's Business Daily
    CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy
    Clovis Oncology (CLVS) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. 
    Via InvestorPlace
    Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering
    Via Benzinga
    Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
    From Erasca, Inc.
    Via GlobeNewswire
    3 Hot Stocks That Could Live Up to Their Lofty Valuations
    These companies have long runways of growth ahead 
    Via The Motley Fool
    MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs
    Via Benzinga
    Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo
    Via Benzinga
    BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member
    Via Investor Brand Network
    Exposures COVID-19
    Why CSL Ltd Stock Could Be Worth a Look
    FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
    Via MarketBeat
    Exposures Product Safety
    First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
    By Rachael Green, Benzinga 
    Via News Direct
    First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
    On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break... 
    Via TheNewswire.com
    < Previous 1 2
    ...
    17 18 19 20 21 22 23 24 25
    ...
    42 43 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.